These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35247472)

  • 21. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
    Maasoumy B; Vermehren J; Welker MW; Bremer B; Perner D; Höner Zu Siederdissen C; Deterding K; Lehmann P; Cloherty G; Reinhardt B; Pawlotsky JM; Manns MP; Zeuzem S; Cornberg M; Wedemeyer H; Sarrazin C
    J Hepatol; 2016 Sep; 65(3):473-82. PubMed ID: 27085252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
    Sarwar S; Tarique S; Aleem A; Khan AA
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1035-1039. PubMed ID: 31274596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
    Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
    Yada M; Miyazaki M; Tanaka K; Masumoto A; Motomura K
    World J Gastroenterol; 2018 Apr; 24(13):1478-1485. PubMed ID: 29632428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
    Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
    Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
    Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.
    Todt D; Walter S; Brown RJ; Steinmann E
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27754363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
    Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
    J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
    Ferreira VL; Assis Jarek NA; Tonin FS; Borba HH; Wiens A; Muzzillo DA; Pontarolo R
    J Gastroenterol Hepatol; 2017 Apr; 32(4):749-755. PubMed ID: 27785825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
    Shafran SD; Shaw D; Charafeddine M; Agarwal K; Foster GR; Abunimeh M; Pilot-Matias T; Pothacamury RK; Fu B; Cohen E; Cohen DE; Gane E
    J Viral Hepat; 2018 Feb; 25(2):118-125. PubMed ID: 28833938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM
    J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Gut; 2016 Nov; 65(11):1861-1870. PubMed ID: 27605539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
    Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.